Genetic regulation of endothelial function

L C Jones, A D Hingorani

The healthy vascular endothelium exerts atheroprotective actions through vasoactive mediators such as nitric oxide (NO), prostacyclin, and endothelium derived hyperpolarising factor (EDHF). There is evidence that as the endothelium ages, it is exposed to the damaging effects of raised blood pressure and increased concentrations of cholesterol, glucose, homocysteine, to products of the inflammatory response, and to the constituents of cigarette smoke, and these protective properties diminish leading to a state of endothelial dysfunction.1 Endothelial dysfunction can be detected in forearm or coronary arteries in vivo, before the development of clinical atherosclerosis, as an impairment of endothelium dependent agonist or flow mediated vasodilation.2 Endothelial dysfunction by these methods correlates with cardiovascular risk factors,3 and may be predictive of incident cardiovascular events.4 Children with certain single gene disorders such as homocystinuria and familial hypercholesterolaemia, at risk of premature atherosclerosis, also exhibit early endothelial dysfunction.5 6 Although the more common forms of atherosclerosis manifest later in life, twin and adoption studies indicate that this more common form is also partly heritable,7 though inheritance is complex, arising as a result of common environmental exposures (risk factors) and many common gene variants (polymorphisms) with small to moderate effect. In common with other complex disorders, the genetic effect sizes in question are probably smaller then small, and the findings are inconsistent probably because the genetic studies, whether of intermediate phenotypes or of clinical outcomes, need to be much larger to provide reliable assessment of small but potentially important genetic effects.8 9 This article provides a brief overview of the most studied genes.

VARIATION IN NITRIC OXIDE REGULATORY GENES, ENDOTHELIAL DYSFUNCTION, AND ATHEROSCLEROSIS

Studies of normal NO synthesis suggest potential mechanisms to account for decreased NO availability that could underlie vascular disease. The factors and pathways of potential importance are illustrated in fig 1. Decreased NO bioavailability could result from reduced expression or activity of endothelial nitric oxide synthase (eNOS), increased generation of asymmetric dimethylarginine (ADMA; an endogenous circulating inhibitor of NOS), decreased availability of 6R-tetrahydrobiopterin (BH4; an essential NOS co-factor), or increased inactivation of NO by reactive oxygen species (ROS) such as superoxide (O_2^-).10

GENETIC VARIATION IN NITRIC OXIDE REGULATORY GENES

Polymorphisms in the eNOS gene, NOS 3

The NOS 3 gene has been the focus of intensive research to identify potentially functional polymorphisms or mutations that might influence expression or activity. To date more than 100 polymorphisms have been identified in, or in the vicinity of, the gene (NCBI SNP database, http://www.ncbi.nlm.nih.gov/SNP/).

More than 15 polymorphisms exist in the NOS3 promoter that might influence mRNA transcription and reduce gene expression. The −786T/C promoter polymorphism influenced transcriptional activity in vitro in a luciferase/reporter assay system and was associated with coronary arterial spasm in Japanese subjects.11 In one study, endothelial cells from subjects with the CC genotype exhibited reduced shear stress induced eNOS mRNA transcription, and vascular rings from such subjects had diminished endothelium dependent vasodilation.12 However, the −786T/C polymorphism has shown inconsistent associations with functional measures, and with clinical disease end points. A recent meta-analysis of studies involving 4882 cases and 9366 controls provided marginal evidence of increased risk among CC subjects (odds ratio 1.30, 95% confidence interval (CI) 1.01 to 1.66; p = 0.04).13

Polymorphisms within the coding region of the NOS 3 gene could alter NOS enzymatic activity. One of the most studied eNOS polymorphisms (894G>T) within exon 7 is the only common polymorphism identified thus far that encodes an amino acid substitution—Glu298Asp (glutamate to aspartate at position 298).14 There is now a considerable debate as to whether this polymorphism is functional. Two studies have shown that eNOS Asp298 is subject to selective proteolytic cleavage in endothelial cells and vascular tissues that might account for reduced vascular NO generation.15 However, other studies suggest this finding might be artefactual.16 If this is the case, eNOS Asp298 might merely be a marker for another possibly functional variant elsewhere in the gene. Data from physiological studies have also been inconsistent. In some studies, individuals with the Asp298 allele exhibited altered vascular responses—for example, a reduced blood pressure fall following exercise training, a lower basal blood flow and reduced vasodilation to adenosine in the coronary...
Polymorphisms in genes regulating ADMA

Endogenous asymmetric methylarginines might have a profound effect on NO synthesis by inhibiting the NOS enzyme. ADMA, an analogue of the NOS substrate L-arginine, is raised in various cardiovascular disease states, 19 including hypertension, renal failure, and peripheral arterial occlusive disease. ADMA is removed from the circulation via metabolism by two isoforms of dimethylarginine dimethylaminohydrolases (DDAH), the DDAH2 isoform predominating in tissues expressing eNOS, such as the endothelium. The cause of raised ADMA in patients at risk of vascular disease is unknown, but common genetic variation within the DDAH enzymes that alter expression or activity might provide one potential explanation. Six polymorphisms have been identified in the DDAH2 gene. Five lie upstream of the translation start site and might influence gene transcription. An insertion deletion polymorphism (6G/7G) at position −871 that lies with the basal promoter region influence DDAH2 promoter activity in a promoter/reporter assay. 20 Additional studies are required to clarify the effect of this variant on ADMA metabolism and endothelial function in vivo.

Polymorphisms in genes regulating BH4

Deficiency of the NOS cofactor, BH4, from reduced synthesis or increased oxidative inactivation could lead to reduced NO availability. When BH4 is limiting, NOS generates $O_2^-$ rather than NO from oxygen and NADPH. 21 The amount of available BH4 depends on rates of synthesis and inactivation. Inactivation of BH4 is probably through reaction with ROS generated within the vessel wall. The de novo production of BH4 is reliant upon three enzymes—GTP cyclohydrolase 1, 6-pyrrovl-tetrahydropterin synthase, and sepiapterin reductase. Local intravascular administration of BH4 to smokers, hypertensives, or hypercholesteroleemics can reinstate normal endothelial function, whereas BH4 has no effect on healthy vessels at the same dose. 22 This observation suggests that BH4 availability may be limited in diseased vessels. The initial step in the BH4 synthesis is the conversion of GTP to dihydropterin triphosphate by GTP cyclohydrolase 1 (GTPCH1), which is rate-limiting. GTPCH-1 expression can be upregulated by cytokines and is associated with elevation of intracellular BH4 in endothelial cells. More than 80 rare mutations have been reported in the human GCH1 gene (BH4 database, http://www.bh4.org), linked with the rare monogenic neurological disorder DOPA responsive dystonia. A recent study has identified two common polymorphisms in the promoter region of the gene that may be associated with plasma concentrations of neopterin (a marker of BH4 synthesis) (Jones LC et al, 2003, unpublished observations). There have been no published studies of variation in gene encoding downstream enzymes in the BH4 synthetic pathway, or of effects on endothelial function.

Polymorphism in the gene encoding the p22phox subunit of NADPH oxidase (CYBA)

ROS mediate oxidation of low density lipoprotein (LDL), and promote smooth muscle cell growth, migration, and apoptosis, all of which occur during atherosclerosis. 22 NO also reacts rapidly with $O_2^-$ to produce ONOO$^-$, which can lead to protein and DNA damage, and results in “quenching” of the atheroprotective functions of NO. ROS may be elevated in disease states such as hypertension, heart failure, hypercholesterolaemia, and diabetes, possibly contributing to the endothelial dysfunction. Reduced inactivation of $O_2^-$, for example, by superoxide dismutase enzymes, might also contribute.

The vasculature is a site of $O_2^-$ generation, 23 through several enzymes including NADPH oxidases, and, under some circumstances, NOS itself. NADPH oxidase expression or activity may be upregulated in diseased blood vessels, and there is interest in genetic variation in one particular subunit of this enzyme complex, p22phox, as a risk factor for vascular disease. Rare mutations of the p22phox gene (CYBA) cause autosomal recessive chronic granulomatous disease, but vascular function has not been systematically investigated in these individuals, and it is not known whether they are less atherosclerosis prone. Small scale studies of a common CYBA C242T polymorphism, that encodes a His72→Tyr substitution in a potential heme binding site, have been conflicting. For example, the 242T allele was associated with reduced NADPH oxidase activity in blood.
vessels from patients with coronary artery disease (CAD)." Carriage of the T allele was also associated with augmented FMD of the brachial artery in 93 patients, 30% of whom had evidence of CAD, suggesting that this allele may exert a protective effect by down regulating O2– production. This was supported by association studies in Japanese subjects in which the 24T allele was present at higher frequency in control subjects than individuals with CAD or coronary spasm. In contrast, the 24T allele was associated with increased progression of CAD and decreased regression of disease upon lipid lowering treatment compared to CC homozygotes in a study of 313 individuals from the lipoprotein and coronary artery study. The C24T polymorphism was not associated with the occurrence or severity of CAD in a cohort of 689 Australian whites. Associations of the C24T variant with endothelial function have also been questioned. Some of these uncertainties might be resolved by systematic reviews and meta-analyses of the relevant genotype–disease association studies.

OTHER POLYMORPHISMS INVESTIGATED FOR ASSOCIATIONS WITH ENDOTHELIAL FUNCTION

Unsurprisingly polymorphisms in a variety of other genes whose products have been implicated in endothelial dysfunction have been tested for associations with endothelium dependent vasoreactivity. These include angiotensin converting enzyme, methylene tetrahydrofolate reductase, neuro-peptide Y, the bradykinin receptor, interleukin-6, osteoprotogerin, glutathione cysteine ligase, and the G-protein β3-subunit. Results have either been inconsistent or data have been limited to single studies, and it has therefore been difficult to draw firm conclusions about these genes. There have also been rather few studies of genes that might regulate the availability other endothelial mediators such as endothelin-1, prostacyclin, and EDHF.

FUTURE APPROACHES

The appreciation that common gene variants may, at best, have small to modest effects on physiology and disease susceptibility has led to the understanding that future studies of complex disease susceptibility, whether they relate to clinical end points or intermediate phenotypes such as endothelial function, will need to be much larger in size. Meta-analysis to pool data from small underpowered studies with inconsistent findings may prove fruitful but there is also a need for larger definitive studies. Non-invasive assessment of vascular function by ultrasound using measures of FMD, pulse wave analysis, and arterial stiffness is now feasible in very large datasets numbering several thousand. The almost unique ability to gather such detailed phenotypic information in large numbers of human subjects which, in the case of FMD, may have independent prognostic significance, will in future offer the opportunity of defining genes that regulate vascular function, and will provide an insight into the interaction between genes and environmental exposures in the development of atherosclerosis.

ACKNOWLEDGEMENTS

ADH is a British Heart Foundation Senior Research Fellow

Authors’ affiliations

L C Jones, A D Hingorani, Centre for Clinical Pharmacology, British Heart Foundation Laboratories, Department of Medicine, University College London, London, UK

Correspondence to: Dr Aroon D Hingorani, Centre for Clinical Pharmacology, BHF Laboratories, Department of Medicine, 5 University Street, London WC1E 6JJ, UK; a.hingorani@ucl.ac.uk

REFERENCES


